CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

76175

CHEMISTRY REVIEW(S)

ANDA APPROVAL SUMMARY

ANDA:	CHEMIST:	DATE:
76-175	Ramesh Sood, Ph.D.	February 11, 2002

DRUG PRODUCT:
Mefloquine Hydrochloride

FIRM:
Geneva Pharmaceutical Technology Corporation

DOSAGE FORM:	STRENGTH:
Tablets	250 mg

cGMP:
EER Pending

BIO:
Bioequivalence was reviewed by Mamata Gokhale and found acceptable on July 31, 2001.

VALIDATION - *(Description of dosage form same as firm's):*
The drug substance and the drug product are non-USP. Methods validation request was submitted to FDA laboratory on October 24, 2001 and the results are pending.

STABILITY:
The firm has provided 3 month accelerated stability data and 18 month room temperature data for the drug product packaged in box of five blisters with each blister containing 5 tablets. In addition, the firm also has submitted 3 month accelerated and room temperature data for the bulk tablets stored in LDPE bags. These stability data support the requested 24 month expiration date for 250 mg strength.

LABELING:
Labeling was reviewed by L. Golson and found satisfactory on 7-Feb-2002.

STERILIZATION VALIDATION *(If applicable)*:
N/A

SIZE OF BIO BATCH *(Firm's source of NDS ok?)*:
The sizes of bio-batch is tablets (Lot # D000301)
The drug substance, Mefloquine Hydrochloride, was manufactured by

SIZE OF STABILITY BATCHES *(If different from bio batch, were they manufactured via the same process?):*
N/A

PROPOSED PRODUCTION BATCH - MANUFACTURING PROCESS THE SAME?:
Manufacturing process is same (Batch size: Tablets).

Signature of chemist:	Signature of supervisor:
/S/	2/12/02

OFFICE OF GENERIC DRUGS

ABBREVIATED NEW DRUG APPLICATION
CHEMISTRY, MANUFACTURING AND CONTROLS REVIEW

1. CHEMIST'S REVIEW NUMBER
1

2. ANDA NUMBER
76-175

3. NAME AND ADDRESS OF APPLICANT
Geneva Pharmaceutical Technology Corporation
Attn: Mahendra Patel, Ph.D.
2400 Route 130
Dayton, NJ 08810

Ph: 732-274-2400 Fax: 732-274-8989

4. LEGAL BASIS for ANDA SUBMISSION
The basis of Geneva's proposed ANDA for Mefloquine Hydrochloride Tablets is RLD, Larium Tablets (NDA 19591) manufactured by F. Hoffmann-la Roche Ltd., Basel, Switzerland and distributed by Roche Laboratories, Inc., 340 Nutley, NJ. The applicant certifies that the claims of U.S. patent No. 4,579,855 (expiring October 1, 2004), that covers the RLD Larium, are invalid, unenforceable and/or will not be infringed by the manufacture, use or sale of the Mefloquine Tablets (V1.1, June 7 correspondence). GPTC also certifies that there are no exclusivities associated with the approved listed drug product, Larium Tablets 250 mg.

5. SUPPLEMENT(s)
None

6. NAME OF DRUG
Mefloquine Hydrochloride

7. NONPROPRIETARY NAME
Mefloquine Hydrochloride

8. SUPPLEMENT(s) PROVIDE(s) FOR
None

9. AMENDMENTS AND OTHER DATES
5/23/2001 Original submission
6/7/2001 New Correspondence (Amended patent certification)

10. PHARMACOLOGICAL CATEGORY
Treatment of acute malarial infections.

11. HOW DISPENSED

Prescription

12. RELATED IND/NDA/DMF(s)

Product	Holder	DMF No.	LOA
Mefloquine Hydrochloride			V. 1.10, p. 4585
Blister card component manufacturer			V. 1.10, p. 4999
Packaging site for blister packaging			V. 1.10, p. 4998

13. DOSAGE FORM

Tablets

14. POTENCY

250 mg.

15. CHEMICAL NAME AND STRUCTURE

Mefloquine hydrochloride: (R*,S*)-(±)-α-2-Piperidinyl-2,8-bis (trifluoremethyl)-4-quinilinemethanol hydrochloride; MW 414.78, CAS-No 51773-92-3



16. RECORDS AND REPORTS

None

17. COMMENTS

The following sections are unsatisfactory: synthesis, raw material control, container, laboratory controls, and stability.

18. CONCLUSIONS AND RECOMMENDATIONS

The application is not approvable [Minor Amendment].

19. REVIEWER AND DATE COMPLETED

Ramesh Sood, Ph.D./July 24, 2001

Redacted 14

pages of trade

secret and/or

confidential

commercial

information

Chem Review #1

OFFICE OF GENERIC DRUGS

ABBREVIATED NEW DRUG APPLICATION
CHEMISTRY, MANUFACTURING AND CONTROLS REVIEW

1. CHEMIST'S REVIEW NUMBER
2

2. ANDA NUMBER
76-175

3. NAME AND ADDRESS OF APPLICANT
Geneva Pharmaceutical Technology Corporation
Attn: Pankaj Dave
2400 Route 130
Dayton, NJ 08810

Ph: 732-274-2400 Fax: 732-274-8989

4. LEGAL BASIS for ANDA SUBMISSION
The basis of Geneva's proposed ANDA for Mefloquine Hydrochloride Tablets is RLD, Larium Tablets (NDA 19591) manufactured by F. Hoffmann-la Roche Ltd., Basel, Switzerland and distributed by Roche Laboratories, Inc., 340 Nutley, NJ. The applicant certifies that the claims of U.S. patent No. 4,579,855 (expiring October 1, 2004), that covers the RLD Larium, are invalid, unenforceable and/or will not be infringed by the manufacture, use or sale of the Mefloquine Tablets (V1.1, June 7 correspondence). GPTC also certifies that there are no exclusivities associated with the approved listed drug product, Larium Tablets 250 mg.

5. SUPPLEMENT(s)
None

6. PROPRIETARY NAME OF DRUG
N/A

7. NONPROPRIETARY NAME
Mefloquine Hydrochloride

8. SUPPLEMENT(s) PROVIDE(s) FOR
None

9. AMENDMENTS AND OTHER DATES

5/23/2001	Original submission
6/7/2001	New Correspondence (Amended patent certification)
7/2/2001	New Correspondence (Patent Amendment)
7/11/2001	Telephone Bio Amendment
7/30/2001	Patent Amendment
10/12/2001	Minor Amendment
10/25/2001	Telephone Amendment

10/26/2001 Labeling Amendment
11/5/2001 Labeling Amendment

10. PHARMACOLOGICAL CATEGORY

Treatment of acute malarial infections.

11. HOW DISPENSED

Prescription

12. RELATED IND/NDA/DMF(s)

Product	Holder	DMF No.	LOA
Mefloquine Hydrochloride			V. 1.10, p. 4585
Blister card component manufacturer			V. 1.10, p. 4999
Packaging site for blister packaging			V. 1.10, p. 4998

13. DOSAGE FORM

Tablets

14. POTENCY

250 mg.

15. CHEMICAL NAME AND STRUCTURE

Mefloquine hydrochloride: (R*,S*)-(±)-α-2-Piperidinyl-2,8-bis (trifluoremethyl)-4-quinilinemethanol hydrochloride; MW 414.78, CAS-No 51773-92-3



HCl

16. RECORDS AND REPORTS

None

17. COMMENTS

EER is pending. Methods validation results from FDA laboratory are awaited.

18. CONCLUSIONS AND RECOMMENDATIONS

The application is approvable pending EER.

19. REVIEWER AND DATE COMPLETED

Ramesh Sood, Ph.D./February 11, 2002

APPEARS THIS WAY
ON ORIGINAL

Redacted 12

pages of trade

secret and/or

confidential

commercial

information

Chem-Review #2

AUG - 8 2001

38. CHEMISTRY COMMENTS TO BE PROVIDED TO THE APPLICANT

ANDA: 76-175

APPLICANT: Geneva Pharmaceuticals Technology Corporation

DRUG PRODUCT: Mefloquine Hydrochloride Tablets, 250 mg.

The deficiencies presented below represent **Minor** deficiencies.

A. Deficiencies:

B. In addition to responding to the above deficiencies, please note and acknowledge the following comments in your response:

1. Your labeling information is pending review. Deficiencies, if any, will be communicated separately.

2. Your bioequivalency information is pending review. Deficiencies, if any, will be communicated separately.

3. All facilities referenced in the ANDA should have a satisfactory compliance evaluation at the time of approval.

4. We require an acceptable Methods validation to support the ANDA and we will be scheduling this study after all issues related to method validation have been resolved. At that time you will be requested to submit samples. Please provide those requested samples promptly when contacted. Please also provide a commitment to work with us to expeditiously resolve any deficiencies from the Methods validation study if the ANDA is approved prior to its completion.

5. Please provide all available long-term stability data to update your studies.

Sincerely yours,

/S/ for

Rashmikant M. Patel, Ph.D.
Director
Division of Chemistry I
Office of Generic Drugs
Center for Drug Evaluation and Research

ESTABLISHMENT EVALUATION REQUEST
SUMMARY REPORT

Application: **ANDA 76175/000**
Priority:
Org Code: **600**
Stamp: **24-MAY-2001** Regulatory Due:
Action Goal:
District Goal: **24-APR-2002**
Applicant: **GENEVA PHARMS TECH**
2400 RT 130 NORTH
DAYTON, NJ 08810
Brand Name:
Established Name: **MEFLOQUINE HYDROCHLORIDE**
Generic Name:
Dosage Form: **TAB (TABLET)**
Strength: **250 MG**

FDA Contacts: **T. AMES** **(HFD-640)** **301-827-5849 , Project Manager**
P. SCHWARTZ **(HFD-629)** **301-827-5848 , Team Leader**

Overall Recommendation:

Establishment:
DMF No:
AADA No:

Profile: **CSN** OAI Status: **NONE**
Last Milestone: **ASSIGNED INSPECTION TO IB**
Milestone Date: **28-JUN-2001**
Responsibilities: **DRUG SUBSTANCE MANUFACTURER**

Establishment: **2247859**
GENEVA PHARMACEUTICALS TECI
2400 RT 130 NORTH
DAYTON, NJ 08810
DMF No:
AADA No:

Profile: **TCM** OAI Status: **NONE**
Last Milestone: **SUBMITTED TO DO**
Milestone Date: **27-JUN-2001**
Responsibilities: **FINISHED DOSAGE MANUFACTURER**

Establishment:
DMF No:
AADA No:

Profile: **TCM** OAI Status: **NONE**
Last Milestone: **SUBMITTED TO OC**
Milestone Date: **07-AUG-2001**
Responsibilities: **FINISHED DOSAGE PACKAGER**

ESTABLISHMENT EVALUATION REQUEST
DETAIL REPORT

Application: ANDA 76175/000
Stamp: 24-MAY-2001
Regulatory Due:
Applicant: GENEVA PHARMS TECH
2400 RT 130 NORTH
DAYTON, NJ 08810
Priority:
Org Code: 600

Action Goal:
District Goal: 24-APR-2002
Brand Name:
Estab. Name: MEFLOQUINE HYDROCHLORIDE
Generic Name:
Dosage Form: (TABLET)
Strength: 250 MG

Application Comment:
FDA Contacts: T. AMES (HFD-640) 301-827-5849 , Project Manager
P. SCHWARTZ (HFD-629) 301-827-5848 , Team Leader

Overall Recommendation:
Establishment:

DMF No:
AADA:
Responsibilities: DRUG SUBSTANCE MANUFACTURER
Profile: CSN
OAI Status: NONE
Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	27-JUN-2001				MIDDLETONS

Establishment: 2247859
GENEVA PHARMACEUTICALS TECHNOLOGY CORP
2400 RT 130 NORTH
DAYTON, NJ 08810
DMF No:
AADA:
Responsibilities: FINISHED DOSAGE MANUFACTURER
Profile: TCM
OAI Status: NONE
Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	27-JUN-2001				MIDDLETONS